Alkem launches favipiravir under brand name Alfluenza

Favipiravir is approved by the DCGI restricted emergency use in India for the treatment of mild to moderate cases of COVID-19
Read Article

Alkem Laboratories has launched Favipiravir under the brand name ‘Alfluenza’ in India for the management of mild to moderate cases of COVID-19.

Favipiravir is approved by the DCGI for restricted emergency use in India.

Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

 

AfluenzaAlkemCOVID-19Favipiravir
Comments (0)
Add Comment